Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 718Lung Neoplasms 310Small Cell Lung Carcinoma 111Neoplasms 42Adenocarcinoma of Lung 40Neoplasm Metastasis 35Parkinson Disease 4, Autosomal Dominant Lewy Body 22Brain Neoplasms 21Carcinoma 19Breast Neoplasms 18Lung Diseases 15NSCLC 14Mesothelioma, Malignant 14Thoracic Neoplasms 13Adenocarcinoma, Bronchiolo-Alveolar 13Prostatic Neoplasms 11Pleural Effusion, Malignant 10Non-Squamous Non-Small Cell Lung Cancer 10Mesothelioma 10Cachexia 10Respiratory Tract Neoplasms 9Pain 9Bronchial Neoplasms 9Respiratory Tract Diseases 8Carcinoma, Squamous Cell 8Carcinoma, Bronchogenic 8Adenocarcinoma 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7

Interventions

anlotinib 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Extensive Small Cell Lung Cancer × Thoracic × Clear all
NCT04234607 2020-01-22

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
738 enrolled
Thoracic

Extensive Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡